However, studies have since also shown that IL-17 inhibition may interfere with dysregulation of the gut epithelial barrier, predisposing to infection and inflammation which can, in turn, exacerbate or trigger IBD [98]. This evidence concerns the gene IL17A and inflammatory bowel disease.